Design of pathway preferential estrogens that provide beneficial metabolic and vascular effects without stimulating reproductive tissues

Science Signaling

Volumn 9, Issue 429, 2016, Pages

  Madak Erdogan, Zeynep ^a   Kim, Sung Hoon ^b   Gong, Ping ^a   Zhao, Yiru C ^a   Zhang, Hui ^c   Chambliss, Ken L ^c   Carlson, Kathryn E ^b   Mayne, Christopher G ^b   Shaul, Philip W ^c   Korach, Kenneth S ^d   Katzenellenbogen, John A ^b   Katzenellenbogen, Benita S ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR ALPHA; LIGAND; PROTEIN BINDING;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BODY WEIGHT; CHROMATIN; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFECT; GENE CONTROL; HUMAN; HUMAN CELL; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; WEIGHT GAIN; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; KNOCKOUT MOUSE; MAPK SIGNALING; MCF-7 CELL LINE; METABOLISM; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; UDDER; UTERUS;

ADIPOSE TISSUE; ANIMALS; BODY WEIGHT; CELL PROLIFERATION; CHROMATIN; DRUG DESIGN; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LIGANDS; LIVER; MAMMARY GLANDS, ANIMAL; MAP KINASE SIGNALING SYSTEM; MCF-7 CELLS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; UTERUS;

EID: 84971350913     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.aad8170     Document Type: Article

References (65)

1. Z. Bai, R. Gust, Breast cancer, estrogen receptor and ligands. Arch. Pharm. 342, 133-149 (2009).
2. B. J. Deroo, K. S. Korach, Estrogen receptors and human disease. J. Clin. Invest. 116, 561-570 (2006).
3. E. M. Fox, R. J. Davis, M. A. Shupnik, ERb in breast cancer-Onlooker, passive player, or active protector? Steroids 73, 1039-1051 (2008).
4. C. Osipo, H. Liu, K. Meeke, V. C. Jordan, The consequences of exhaustive antiestrogen therapy in breast cancer: Estrogen-induced tumor cell death. Exp. Biol.Med. 229, 722-731 (2004).
5. S. Banerjee, K. L. Chambliss, C. Mineo, P. W. Shaul, Recent insights into non-nuclear actions of estrogen receptor alpha. Steroids 81, 64-69 (2014).
6. S. R. Hammes, E. R. Levin, Minireview: Recent advances in extranuclear steroid receptor actions. Endocrinology 152, 4489-4495 (2011).
7. S. Clark, J. Rainville, X. Zhao, B. S. Katzenellenbogen, D. Pfaff, N. Vasudevan, Estrogen receptor-mediated transcription involves the activation of multiple kinase pathways in neuroblastoma cells. J. Steroid Biochem. Mol. Biol. 139, 45-53 (2014).
8. W. R. Harrington, S. H. Kim, C. C. Funk, Z. Madak-Erdogan, R. Schiff, J. A. Katzenellenbogen, B. S. Katzenellenbogen, Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. Mol. Endocrinol. 20, 491-502 (2006).
9. Z. Madak-Erdogan, T.-H. Charn, Y. Jiang, E. T. Liu, J. A. Katzenellenbogen, B. S. Katzenellenbogen, Integrative genomics of gene and metabolic regulation by estrogen receptors a and b, and their coregulators. Mol. Syst. Biol. 9, 676 (2013).
10. Z. Madak-Erdogan, K. J. Kieser, S. H. Kim, B. Komm, J. A. Katzenellenbogen, B. S. Katzenellenbogen, Nuclear and extranuclear pathway inputs in the regulation of global gene expression by estrogen receptors. Mol. Endocrinol. 22, 2116-2127 (2008).
11. Z. Madak-Erdogan, M. Lupien, F. Stossi, M. Brown, B. S. Katzenellenbogen, Genomic collaboration of estrogen receptor a and extracellular signal-regulated kinase 2 in regulating gene and proliferation programs. Mol. Cell. Biol. 31, 226-236 (2011).
12. N. Vasudevan, L.-M. Kow, D. W. Pfaff, Early membrane estrogenic effects required for full expression of slower genomic actions in a nerve cell line. Proc. Natl. Acad. Sci. U.S.A. 98, 12267-12271 (2001).
13. A. C. Gee, K. E. Carlson, P. G. V. Martini, B. S. Katzenellenbogen, J. A. Katzenellenbogen, Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor. Mol. Endocrinol. 13, 1912-1923 (1999).
14. J. S. Wright, H. Shadnia, J. M. Anderson, T. Durst, M. Asim, M. El-Salfiti, C. Choueiri, M. A. C. Pratt, S. C. Ruddy, R. Lau, K. E. Carlson, J. A. Katzenellenbogen, P. J. O'Brien, L. Wan, A-CD estrogens. I. Substituent effects, hormone potency, and receptor subtype selectivity in a new family of flexible estrogenic compounds. J. Med. Chem. 54, 433-448 (2011).
15. G. M. Anstead, K. E. Carlson, J. A. Katzenellenbogen, The estradiol pharmacophore: Ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 62, 268-303 (1997).
16. D. Lesuisse, E. Albert, F. Bouchoux, E. Cérède, J.-M. Lefrançois, M.-O. Levif, S. Tessier, B. Tric, G. Teutsch, Biphenyls as surrogates of the steroidal backbone. Part 1: Synthesis and estrogen receptor affinity of an original series of polysubstituted biphenyls. Bioorg. Med. Chem. Lett. 11, 1709-1712 (2001).
17. F. Paris, P. Balaguer, B. Térouanne, N. Servant, C. Lacoste, J.-P. Cravedi, J. C. Nicolas, C. Sultan, Phenylphenols, biphenols, bisphenol-A and 4-tert-octylphenol exhibit a and b estrogen activities and antiandrogen activity in reporter cell lines. Mol. Cell. Endocrinol. 193, 43-49 (2002).
18. K. E. Carlson, I. Choi, A. Gee, B. S. Katzenellenbogen, J. A. Katzenellenbogen, Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: Evidence that an open pocket conformation is required for ligand interaction. Biochemistry 36, 14897-14905 (1997).
19. M. Jeyakumar, K. E. Carlson, J. R. Gunther, J. A. Katzenellenbogen, Exploration of dimensions of estrogen potency: Parsing ligand binding and coactivator binding affinities. J. Biol. Chem. 286, 12971-12982 (2011).
20. M. Jeyakumar, J. A. Katzenellenbogen, A dual-acceptor time-resolved Föster resonance energy transfer assay for simultaneous determination of thyroid hormone regulation of corepressor and coactivator binding to the thyroid hormone receptor: Mimicking the cellular context of thyroid hormone action. Anal. Biochem. 386, 73-78 (2009).
21. S. M. Bartell, L. Han, H.-n. Kim, S. H. Kim, J. A. Katzenellenbogen, B. S. Katzenellenbogen, K. L. Chambliss, P. W. Shaul, P. K. Roberson, R. S. Weinstein, R. L. Jilka, M. Almeida, S. C. Manolagas, Non-nuclear-initiated actions of the estrogen receptor protect cortical bone mass. Mol. Endocrinol. 27, 649-656 (2013).
22. K. L. Chambliss, Q. Wu, S. Oltmann, E. S. Konaniah, M. Umetani, K. S. Korach, G. D. Thomas, C. Mineo, I. S. Yuhanna, S. H. Kim, Z. Madak-Erdogan, A. Maggi, S. P. Dineen, C. L. Roland, D. Y. Hui, R. A. Brekken, J. A. Katzenellenbogen, B. S. Katzenellenbogen, P. W. Shaul, Non-nuclear estrogen receptor a signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J. Clin. Invest. 120, 2319-2330 (2010).
23. S. Kato, H. Endoh, Y. Masuhiro, T. Kitamoto, S. Uchiyama, H. Sasaki, S. Masushige, Y. Gotoh, E. Nishida, H. Kawashima, D. Metzger, P. Chambon, Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270, 1491-1494 (1995).
24. V. Albert, M. N. Hall, mTOR signaling in cellular and organismal energetics. Curr. Opin. Cell Biol. 33, 55-66 (2015).
25. G. Jia, A. R. Aroor, L. A. Martinez-Lemus, J. R. Sowers, Overnutrition, mTOR signaling, and cardiovascular diseases. Am. J. Physiol. Regul. Integr. Comp. Physiol. 307, R1198-R1206 (2014).
26. A. L. Zoller, G. J. Kersh, Estrogen induces thymic atrophy by eliminating early thymic progenitors and inhibiting proliferation of b-selected thymocytes. J. Immunol. 176, 7371-7378 (2006).
27. J. L. Yecies, H. H. Zhang, S. Menon, S. Liu, D. Yecies, A. I. Lipovsky, C. Gorgun, D. J. Kwiatkowski, G. S. Hotamisligil, C. H. Lee, B. D. Manning, Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab. 14, 21-32 (2011).
28. J. L. Yecies, B. D. Manning, Transcriptional control of cellular metabolism by mTOR signaling. Cancer Res. 71, 2815-2820 (2011).
29. N. Higuchi, M. Kato, Y. Shundo, H. Tajiri, M. Tanaka, N. Yamashita, M. Kohjima, K. Kotoh, M. Nakamuta, R. Takayanagi, M. Enjoji, Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol. Res. 38, 1122-1129 (2008).
30. S. W. Beaven, A. Matveyenko, K. Wroblewski, L. Chao, D. Wilpitz, T. W. Hsu, J. Lentz, B. Drew, A. L. Hevener, P. Tontonoz, Reciprocal regulation of hepatic and adipose lipogenesis by liver X receptors in obesity and insulin resistance. Cell Metab. 18, 106-117 (2013).
31. T. Tchkonia, T. Thomou, Y. Zhu, I. Karagiannides, C. Pothoulakis, M. D. Jensen, J. L. Kirkland, Mechanisms and metabolic implications of regional differences among fat depots. Cell Metab. 17, 644-656 (2013).
32. D. P. McDonnell, S. E. Wardell, The molecular mechanisms underlying the pharmacological actions of ER modulators: Implications for new drug discovery in breast cancer. Curr. Opin. Pharmacol. 10, 620-628 (2010).
33. E. Swedenborg, K. A. Power, W. Cai, I. Pongratz, J. Rüegg, Regulation of estrogen receptor beta activity and implications in health and disease. Cell. Mol. Life Sci. 66, 3873-3894 (2009).
34. E. C. Chang, T. H. Charn, S.-H. Park, W. G. Helferich, B. Komm, J. A. Katzenellenbogen, B. S. Katzenellenbogen, Estrogen receptors a and b as determinants of gene expression: Influence of ligand, dose, and chromatin binding. Mol. Endocrinol. 22, 1032-1043 (2008).
35. E. C. Chang, J. Frasor, B. Komm, B. S. Katzenellenbogen, Impact of estrogen receptor b on gene networks regulated by estrogen receptor a in breast cancer cells. Endocrinology 147, 4831-4842 (2006).
36. S. M. Moore, A. J. Khalaj, S. Kumar, Z. Winchester, J. Yoon, T. Yoo, L. Martinez-Torres, N. Yasui, J. A. Katzenellenbogen, S. K. Tiwari-Woodruff, Multiple functional therapeutic effects of the estrogen receptor b agonist indazole-Cl in a mouse model of multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 111, 18061-18066 (2014).
37. I. Paterni, C. Granchi, J. A. Katzenellenbogen, F. Minutolo, Estrogen receptors alpha (ERa) and beta (ERb): Subtype-selective ligands and clinical potential. Steroids 90, 13-29 (2014).
38. Y. Zhao, P. Gong, Y. Chen, J. C. Nwachukwu, S. Srinivasan, C. Ko, M. K. Bagchi, R. N. Taylor, K. S. Korach, K. W. Nettles, J. A. Katzenellenbogen, B. S. Katzenellenbogen, Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis. Sci. Transl. Med. 7, 271ra9 (2015).
39. B. Finan, B. Yang, N. Ottaway, K. Stemmer, T. D. Müller, C.-X. Yi, K. Habegger, S. C. Schriever, C. Garcia-Cáceres, D. G. Kabra, J. Hembree, J. Holland, C. Raver, R. J. Seeley, W. Hans, M. Irmler, J. Beckers, M. H. de Angelis, J. P. Tiano, F. Mauvais-Jarvis, D. Perez-Tilve, P. Pfluger, L. Zhang, V. Gelfanov, R. D. DiMarchi, M. H. Tschöp, Targeted estrogen delivery reverses the metabolic syndrome. Nat. Med. 18, 1847-1856 (2012).
40. A. Pedram, M. Razandi, M. Lewis, S. Hammes, E. R. Levin, Membrane-localized estrogen receptor a is required for normal organ development and function. Dev. Cell 29, 482-490 (2014).
41. M. Adlanmerini, R. Solinhac, A. Abot, A. Fabre, I. Raymond-Letron, A.-L. Guihot, F. Boudou, L. Sautier, E. Vessières, S. H. Kim, P. Lière, C. Fontaine, A. Krust, P. Chambon, J. A. Katzenellenbogen, P. Gourdy, P. W. Shaul, D. Henrion, J.-F. Arnal, F. Lenfant, Mutation of the palmitoylation site of estrogen receptor a in vivo reveals tissue-specific roles for membrane versus nuclear actions. Proc. Natl. Acad. Sci. U.S.A. 111, E283-E290 (2014).
42. A. Pedram, M. Razandi, J. K. Kim, F. O'Mahony, E. Y. H. P. Lee, U. Luderer, E. R. Levin, Developmental phenotype of a membrane only estrogen receptor a (MOER) mouse. J. Biol. Chem. 284, 3488-3495 (2009).
43. A. Abot, C. Fontaine, M. Buscato, R. Solinhac, G. Flouriot, A. Fabre, A. Drougard, S. Rajan, M. Laine, A. Milon, I. Muller, D. Henrion, M. Adlanmerini, M.-C. Valéra, A. Gompel, C. Gerard, C. Péqueux, M. Mestdagt, I. Raymond-Letron, C. Knauf, F. Ferriere, P. Valet, P. Gourdy, B. S. Katzenellenbogen, J. A. Katzenellenbogen, F. Lenfant, G. L. Greene, J.-M. Foidart, J.-F. Arnal, The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor a modulation, uncoupling nuclear and membrane activation. EMBO Mol. Med. 6, 1328-1346 (2014).
44. A. Pedram, M. Razandi, F. O'Mahony, H. Harvey, B. J. Harvey, E. R. Levin, Estrogen reduces lipid content in the liver exclusively from membrane receptor signaling. Sci. Signal. 6, ra36 (2013).
45. D. Rai, A. Frolova, J. Frasor, A. E. Carpenter, B. S. Katzenellenbogen, Distinctive actions of membrane-targeted versus nuclear localized estrogen receptors in breast cancer cells. Mol. Endocrinol. 19, 1606-1617 (2005).
46. R. L. Rich, L. R. Hoth, K. F. Geoghegan, T. A. Brown, P. K. LeMotte, S. P. Simons, P. Hensley, D. G. Myszka, Kinetic analysis of estrogen receptor/ligand interactions. Proc. Natl. Acad. Sci. U.S.A. 99, 8562-8567 (2002).
47. S. Kousteni, J.-R. Chen, T. Bellido, L. Han, A. A. Ali, C. A. O'Brien, L. Plotkin, Q. Fu, A. T. Mancino, Y. Wen, A. M. Vertino, C. C. Powers, S. A. Stewart, R. Ebert, A. M. Parfitt, R. S. Weinstein, R. L. Jilka, S. C. Manolagas, Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 298, 843-846 (2002).
48. C. Otto, I. Fuchs, H. Altmann, M. Klewer, G. Schwarz, R. Bohlmann, D. Nguyen, L. Zorn, R. Vonk, K. Prelle, T. Österman, C. Malmström, K.-H. Fritzemeier, In vivo characterization of estrogen receptor modulators with reduced genomic versus nongenomic activity in vitro. J. Steroid Biochem. Mol. Biol. 111, 95-100 (2008).
49. M. Centrella, T. L. McCarthy, W.-Z. Chang, D. C. Labaree, R. B. Hochberg, Estren (4-estren-3a, 17b-diol) is a prohormone that regulates both androgenic and estrogenic transcriptional effects through the androgen receptor. Mol. Endocrinol. 18, 1120-1130 (2004).
50. V. Krishnan, H. A. Bullock, B. C. Yaden, M. Liu, R. J. Barr, C. Montrose-Rafizadeh, K. Chen, J. A. Dodge, H. U. Bryant, The nongenotropic synthetic ligand 4-estren-3a17b-diol is a high-affinity genotropic androgen receptor agonist. Mol. Pharmacol. 67, 744-748 (2005).
51. S. H. Windahl, R. Galien, R. Chiusaroli, P. Clément-Lacroix, F. Morvan, L. Lepescheux, F. Nique, W. C. Horne, M. Resche-Rigon, R. Baron, Bone protection by estrens occurs through non-tissue-selective activation of the androgen receptor. J. Clin. Invest. 116, 2500-2509 (2006).
52. T. Ishikawa, I. S. Yuhanna, J. Umetani, W.-R. Lee, K. S. Korach, P. W. Shaul, M. Umetani, LXRb/estrogen receptor-a signaling in lipid rafts preserves endothelial integrity. J. Clin. Invest. 123, 3488-3497 (2013).
53. S. Dupont, A. Krust, A. Gansmuller, A. Dierich, P. Chambon, M. Mark, Effect of single and compound knockouts of estrogen receptors a (ERa) and b (ERb) on mouse reproductive phenotypes. Development 127, 4277-4291 (2000).
54. S. C. Hewitt, G. E. Kissling, K. E. Fieselman, F. L. Jayes, K. E. Gerrish, K. S. Korach, Biological and biochemical consequences of global deletion of exon 3 from the ERb gene. FASEB J. 24, 4660-4667 (2010).
55. C. Trapnell, L. Pachter, S. L. Salzberg, TopHat: Discovering splice junctions with RNASeq. Bioinformatics 25, 1105-1111 (2009).
56. D. Karolchik, R. Baertsch, M. Diekhans, T. S. Furey, A. Hinrichs, Y. T. Lu, K. M. Roskin, M. Schwartz, C. W. Sugnet, D. J. Thomas, R. J. Weber, D. Haussler, W. J. Kent, The UCSC Genome Browser Database. Nucleic Acids Res. 31, 51-54 (2003).
57. K. D. Pruitt, T. Tatusova, D. R. Maglott, NCBI reference sequences (Ref Seq): A curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res. 35, D61-D65 (2007).
58. G. Dennis Jr., B. T. Sherman, D. A. Hosack, J. Yang, W. Gao, H. C. Lane, R. A. Lempicki, DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 4, P3 (2003).
59. C. Y. McLean, D. Bristor, M. Hiller, S. L. Clarke, B. T. Schaar, C. B. Lowe, A. M. Wenger, G. Bejerano, GREAT improves functional interpretation of cis-regulatory regions. Nat. Biotechnol. 28, 495-501 (2010).
60. T. Liu, J. A. Ortiz, L. Taing, C. A. Meyer, B. Lee, Y. Zhang, H. Shin, S. S. Wong, J. Ma, Y. Lei, U. J. Pape, M. Poidinger, Y. Chen, K. Yeung, M. Brown, Y. Turpaz, X. S. Liu, Cistrome: An integrative platform for transcriptional regulation studies. Genome Biol. 12, R83 (2011).
61. Y. Zhao, S. Park, M. K. Bagchi, R. N. Taylor, B. S. Katzenellenbogen, The coregulator, repressor of estrogen receptor activity (REA), is a crucial regulator of the timing and magnitude of uterine decidualization. Endocrinology 154, 1349-1360 (2013).
62. Z. Madak-Erdogan, R. Ventrella, L. Petry, B. S. Katzenellenbogen, Novel roles for ERK5 and cofilin as critical mediators linking ERa-driven transcription, actin reorganization, and invasiveness in breast cancer. Mol. Cancer Res. 12, 714-727 (2014).
63. S. Appachi, J. Sun, K. L. Chambliss, J. A. Katzenellenbogen, B. S. Katzenellenbogen, P. W. Shaul, E. Murphy, Non-nuclear estrogen receptor activation is protective in cardiac ischemia-reperfusion injury in mice. J. Mol. Cell. Cardiol. 53, S25 (2012).
64. D. Seetharam, C. Mineo, A. K. Gormley, L. L. Gibson, W. Vongpatanasin, K. L. Chambliss, L. D. Hahner, M. L. Cummings, R. L. Kitchens, Y. L. Marcel, D. J. Rader, P. W. Shaul, High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ. Res. 98, 63-72 (2006).
65. A. Tamrazi, K. E. Carlson, J. A. Katzenellenbogen, Molecular sensors of estrogen receptor conformations and dynamics. Mol. Endocrinol. 17, 2593-2602 (2003).